Skip to main content
Premium Trial:

Request an Annual Quote

GnuBio Starts Early-Access Testing of Instrument at Montreal Heart Institute


GnuBio has shipped its first early-access DNA sequencer to the Pharmacogenomics Centre at the Montreal Heart Institute, a plan it had announced last month (IS 6/14/2011).

The goal of the early-access program is to demonstrate the robustness of the instrument and its chemistry and to apply the requirements of a clinical diagnostic workflow, the company said. Michael Phillips, director of the Pharmacogenomics Centre, is a scientific advisor to the company.

Researchers at the institute have already used the system to sequence the TNNT2 gene in a number of clinical samples from a French Canadian cohort. Mutations in that gene have been associated with familial hypertrophic cardiomyopathy.

According to GnuBio, the system sequenced 395 base pairs at 3,000-fold coverage with a per-base accuracy of 99.94 percent, and detected heterozygous mutations at 10-fold coverage with confidence equivalent to a Phred score of 40.

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.